A Multicenter, Open-Label, Phase II Study of Sorafenib in Combination With Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Refractory to One or Two Prior Chemotherapy Regimens.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Erlotinib (Primary) ; Sorafenib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Dec 2008 New trial record.